首页> 美国卫生研究院文献>Genome Medicine >CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2 multicenter randomized controlled clinical trial

【2h】

CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2 multicenter randomized controlled clinical trial

机译：与CEOP相比CEOP / IVE / GDP交替方案是针对新诊断的周围性T细胞淋巴瘤患者的一线治疗：来自2期多中心随机对照临床试验的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

accompanies this paper at 10.1186/s13073-020-00739-0.

机译：本文随附于10.1186 / s13073-020-00739-0。

著录项

期刊名称 Genome Medicine
作者
Ming-Ci Cai; Shu Cheng; Xin Wang; Jian-Da Hu; Yong-Ping Song; Yao-Hui Huang; Zi-Xun Yan; Yu-Jie Jiang; Xiao-Sheng Fang; Xiao-Yun Zheng; Li-Hua Dong; Meng-Meng Ji; Li Wang; Peng-Peng Xu; Wei-Li Zhao;
展开▼
作者单位

展开▼
年(卷),期 2020(12),-1
年度 2020
页码 -1
总页数 13
原文格式 PDF
正文语种
中图分类生化遗传学;生化药理学;
关键词
Peripheral T cell lymphoma; Alternating regimen; CHOP; Overall response rate; Prognosis; Prognostic biomarker;

机译：外周T细胞淋巴瘤;替代方案;CHOP;总体缓解率;预后;预后生物标志物;

相似文献

外文文献

1. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial [J] . Ming-Ci Cai, Shu Cheng, Xin Wang, Genome Medicine . 2020,第1期

机译：CEOP / IVE / GDP交替方案与CEOP相比，作为新诊断的外周T细胞淋巴瘤患者的一线治疗：来自相2，多中心，随机，受控临床试验的结果
2. Erratum: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy (Annals of Hematology (1997) 75 (135-140) DOI: 10.1007/s002770050330)) [J] . FridrikM.A., GreilR., HausmaningerH., Annals of hematology . 2014,第3期

机译：勘误：CEOP / IMVP-Dexa交替化疗和非格司亭与CEOP / IMVP-Dexa交替化疗对侵袭性非霍奇金淋巴瘤（NHL）的随机开放标签III期试验。奥地利医学肿瘤治疗工作组的一项多中心试验（血液学年鉴（1997）75（135-140）DOI：10.1007 / s002770050330）
3. Erratum: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy (Annals of Hematology (1997) 75 (135-140) DOI: 10.1007/s002770050330)) [J] . FridrikM.A., GreilR., HausmaningerH., Annals of hematology . 2014,第3期

机译：错误：随机开放标签第三阶段III试验CEOP / IMVP-DEXA交替化疗和菲拉特的CEOP / IMVP-DEXA交替化疗，用于积极的非霍奇金淋巴瘤（NHL）。奥地利医疗肿瘤治疗工作组的多中心审判（血液学史（1997）75（135-140）DOI：10.1007 / S002770050330））
4. Synbiotic Therapy Significantly Reduces Molecular Markers of Inflammation and Clinical Scores in Patients with Active Ulcerative Colitis; A Randomised Controlled Trial [C] . Controlled Release Society annual meeting . 2004

机译：同步治疗显着减少了活性溃疡性结肠炎患者的炎症和临床评分的分子标记;随机对照试验
5. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
6. A Phase II Study of Cyclophosphamide Etoposide Vincristine and Prednisone (CEOP) Alternating with Pralatrexate (P) as Front Line Therapy for Patients with Peripheral T-Cell Lymphoma (PTCL): Final Results from the T- Cell Consortium Trial [O] . Ranjana H. Advani, Stephen M. Ansell, Mary Jo Lechowicz, -1

机译：环磷酰胺依托泊苷长春新碱和泼尼松（CEOP）交替使用普拉拉特（P）作为外周T细胞淋巴瘤（PTCL）患者的前线治疗的II期研究：T细胞联合试验的最终结果
7. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial [O] . Ranjana H. Advani, Stephen M. Ansell, Mary J. Lechowicz, 2015

机译：环磷酰胺，依托泊苷，长春酮和泼尼松（CEOP）与雷达甲酸甲酸盐（P）作为外周T细胞淋巴瘤患者的前线治疗的II期研究：来自T-Cell Consortium试验的最终结果

CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2 multicenter randomized controlled clinical trial

摘要

著录项

相似文献

相关主题

期刊订阅